{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:52:14Z","timestamp":1771901534029,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["DRF-2011-04-021"],"award-info":[{"award-number":["DRF-2011-04-021"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["090532\/Z\/09\/Z"],"award-info":[{"award-number":["090532\/Z\/09\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT091989\/Z\/10\/Z"],"award-info":[{"award-number":["WT091989\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Innovation Challenge Fund","award":["HICF-1009-026"],"award-info":[{"award-number":["HICF-1009-026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40273-017-0519-z","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T05:31:17Z","timestamp":1501479077000},"page":"845-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-0638","authenticated-orcid":false,"given":"James","family":"Buchanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Wordsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Robbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha J. L.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"519_CR1","unstructured":"National Institute for Health and Care Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Manchester: NICE; 2006."},{"issue":"23","key":"519_CR2","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL. Precision medicine: personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229\u201334.","journal-title":"N Engl J Med."},{"issue":"3","key":"519_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tig.2007.12.007","volume":"24","author":"ER Mardis","year":"2008","unstructured":"Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008;24(3):133\u201341.","journal-title":"Trends Genet."},{"issue":"11","key":"519_CR4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2016.07.018","volume":"22","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, et al. Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(11):1961\u20137.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"519_CR5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.14131","volume":"174","author":"AM Agarwal","year":"2016","unstructured":"Agarwal AM, et al. Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias. Br J Haematol. 2016;174(5):806\u201314.","journal-title":"Br J Haematol."},{"issue":"2","key":"519_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.14221","volume":"175","author":"NBA Roy","year":"2016","unstructured":"Roy NBA, et al. A novel 33-gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias. Br J Haematol. 2016;175(2):318\u201330.","journal-title":"Br J Haematol."},{"issue":"4","key":"519_CR7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","volume":"1","author":"H Beltran","year":"2015","unstructured":"Beltran H, et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015;1(4):466\u201374.","journal-title":"JAMA Oncol."},{"issue":"18","key":"519_CR8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med."},{"issue":"5","key":"519_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med."},{"issue":"15","key":"519_CR10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2217\/pgs.13.183","volume":"14","author":"JS Buchanan","year":"2013","unstructured":"Buchanan JS, Wordsworth SA. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833\u201347.","journal-title":"Pharmacogenomics."},{"key":"519_CR11","unstructured":"National Institute for Health and Care Excellence. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. Manchester: NICE; 2012."},{"key":"519_CR12","unstructured":"National Institute for Health and Care Excellence. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: final appraisal determination. Manchester: NICE; 2015."},{"issue":"8","key":"519_CR13","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","volume":"112","author":"T Zenz","year":"2008","unstructured":"Zenz T, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322\u20139.","journal-title":"Blood."},{"issue":"4","key":"519_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pme.13.33","volume":"10","author":"R Alsolami","year":"2013","unstructured":"Alsolami R, Knight SJL, Schuh A. Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia? Pers Med. 2013;10(4):361\u201376.","journal-title":"Pers Med."},{"issue":"9747","key":"519_CR15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet."},{"issue":"7","key":"519_CR16","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2012.13","volume":"26","author":"SJ Knight","year":"2012","unstructured":"Knight SJ, et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia. 2012;26(7):1564\u201375.","journal-title":"Leukemia"},{"issue":"12","key":"519_CR17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood."},{"key":"519_CR18","doi-asserted-by":"crossref","unstructured":"Oscier D, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. London: British Committee for Standards in Haematology; 2012.","DOI":"10.1111\/bjh.12067"},{"issue":"7","key":"519_CR19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","volume":"26","author":"S Pospisilova","year":"2012","unstructured":"Pospisilova S, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458\u201361.","journal-title":"Leukemia."},{"issue":"5","key":"519_CR20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2353\/jmoldx.2008.080033","volume":"10","author":"SR Gunn","year":"2008","unstructured":"Gunn SR, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10(5):442\u201351.","journal-title":"J Mol Diagn."},{"issue":"7","key":"519_CR21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","volume":"123","author":"R Clifford","year":"2014","unstructured":"Clifford R, et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood. 2014;123(7):1021\u201331.","journal-title":"Blood."},{"issue":"12","key":"519_CR22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med."},{"issue":"12","key":"519_CR23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cancergen.2011.10.012","volume":"204","author":"L Zhang","year":"2011","unstructured":"Zhang L, et al. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. Cancer Genet. 2011;204(12):654\u201365.","journal-title":"Cancer Genet."},{"issue":"24","key":"519_CR24","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","volume":"120","author":"J Edelmann","year":"2012","unstructured":"Edelmann J, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120(24):4783\u201394.","journal-title":"Blood."},{"issue":"26","key":"519_CR25","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","volume":"114","author":"J Malcikova","year":"2009","unstructured":"Malcikova J, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114(26):5307\u201314.","journal-title":"Blood."},{"issue":"11","key":"519_CR26","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2010-12-327858","volume":"118","author":"P Ouillette","year":"2011","unstructured":"Ouillette P, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118(11):3051\u201361.","journal-title":"Blood."},{"issue":"21","key":"519_CR27","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247\u201354.","journal-title":"Blood."},{"issue":"29","key":"519_CR28","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473\u20139.","journal-title":"J Clin Oncol."},{"issue":"13","key":"519_CR29","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589\u201397.","journal-title":"Blood."},{"issue":"3","key":"519_CR30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med."},{"key":"519_CR31","unstructured":"Comer B. Ibrutinib\u2019s breakthrough to market. 2013. http:\/\/www.pharmexec.com\/ibrutinibs-breakthrough-market . Accessed 18 May 2017."},{"key":"519_CR32","volume-title":"British national formulary","author":"Joint Formulary Committee","year":"2014","unstructured":"Joint Formulary Committee. British national formulary. London: BMJ Group and Pharmaceutical Press; 2014."},{"key":"519_CR33","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Manchester: NICE; 2017."},{"key":"519_CR34","unstructured":"Follows GA, et al. Interim statement from the BCSH CLL guidelines panel. British Committee for Standards in Haematology; 2015. http:\/\/docplayer.net\/21070184-Interim-statement-from-the-bcsh-cllguidelines-panel.html . Accessed 29 Jan 2017."},{"issue":"16","key":"519_CR35","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497\u2013506.","journal-title":"Blood."},{"issue":"2","key":"519_CR36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","volume":"16","author":"MZ Farooqui","year":"2015","unstructured":"Farooqui MZ, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169\u201376.","journal-title":"Lancet Oncol."},{"issue":"1","key":"519_CR37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 2014;15(1):48\u201358.","journal-title":"Lancet Oncol."},{"key":"519_CR38","unstructured":"Department of Health. NHS reference costs 2012\u20132013. 2014. https:\/\/www.gov.uk\/government\/collections\/nhs-reference-costs#published-reference-costs . Accessed 18 May 2017."},{"key":"519_CR39","doi-asserted-by":"crossref","unstructured":"Department of Health. Drugs and pharmaceutical electronic market information (eMit). 2014. https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit . Accessed 29 Jan 2017.","DOI":"10.4324\/9780203793633-2"},{"key":"519_CR40","volume-title":"Unit costs of health and social care","author":"L Curtis","year":"2014","unstructured":"Curtis L. Unit costs of health and social care. Kent: Personal Social Services Research Unit, University of Kent; 2014."},{"key":"519_CR41","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Manchester: NICE; 2013."},{"key":"519_CR42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","journal-title":"Health Qual Life Outcomes."},{"key":"519_CR43","unstructured":"Napp Pharmaceuticals Ltd. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Napp; 2010. https:\/\/www.nice.org.uk\/guidance\/ta216\/history . Accessed 29 Jan 2017."},{"issue":"5","key":"519_CR44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479\u2013500.","journal-title":"Pharmacoeconomics."},{"key":"519_CR45","first-page":"203","volume-title":"Economic evaluation in health care: merging theory with practice","author":"AH Briggs","year":"2001","unstructured":"Briggs AH. Handling uncertainty in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001. p. 203."},{"issue":"10","key":"519_CR46","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA."},{"issue":"5","key":"519_CR47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-015-0367-7","volume":"34","author":"S Fre","year":"2016","unstructured":"Fre S, Blankart CR, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. Pharmacoeconomics. 2016;34(5):479\u201398.","journal-title":"Pharmacoeconomics."},{"key":"519_CR48","unstructured":"Drummond MF, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005."},{"key":"519_CR49","volume-title":"Economic evaluation in health care: merging theory with practice","author":"M Drummond","year":"2002","unstructured":"Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2002."},{"key":"519_CR50","volume-title":"Applied methods of cost-benefit analysis in health care","year":"2010","unstructured":"McIntosh E, et al., editors. Applied methods of cost-benefit analysis in health care. Oxford: Oxford University Press; 2010."},{"issue":"4","key":"519_CR51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335\u201344.","journal-title":"Pharmacoeconomics."},{"issue":"2","key":"519_CR52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1017\/S0266462312000062","volume":"28","author":"SS Tan","year":"2012","unstructured":"Tan SS, et al. Update of the Dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28(2):152\u20138.","journal-title":"Int J Technol Assess Health Care."},{"key":"519_CR53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-8-32","volume":"8","author":"CR Blankart","year":"2013","unstructured":"Blankart CR, et al. Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis. 2013;8:32.","journal-title":"Orphanet J Rare Dis."},{"key":"519_CR54","unstructured":"Finney A, et al. Cancer\u2019s hidden price tag: revealing the costs behind the illness. Macmillan Cancer Support; 2013. http:\/\/bit.ly\/2rmuDFM . Accessed 29 Jan 2017."},{"issue":"5","key":"519_CR55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361\u20137.","journal-title":"Pharmacoeconomics."},{"issue":"11","key":"519_CR56","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40273-016-0425-9","volume":"34","author":"CP Iglesias","year":"2016","unstructured":"Iglesias CP, et al. Reporting guidelines for the use of expert judgement in model-based economic evaluations. Pharmacoeconomics. 2016;34(11):1161\u201372.","journal-title":"Pharmacoeconomics."},{"key":"519_CR57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fpubh.2016.00214","volume":"4","author":"G Iskrov","year":"2016","unstructured":"Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for assessment and appraisal of orphan drugs. Front Public Health. 2016;4:214.","journal-title":"Front Public Health."},{"issue":"3","key":"519_CR58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40273-014-0235-x","volume":"33","author":"M Paulden","year":"2015","unstructured":"Paulden M, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255\u201369.","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"519_CR59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-016-0388-0","volume":"11","author":"K Kolasa","year":"2016","unstructured":"Kolasa K, et al. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016;11(1):23.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"519_CR60","first-page":"175","volume":"29","author":"DA Goldstein","year":"2015","unstructured":"Goldstein DA, Shaib WL, Flowers CR. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park). 2015;29(3):175\u201383.","journal-title":"Oncology (Williston Park)."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0519-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0519-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0519-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T16:48:12Z","timestamp":1569948492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0519-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0519-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}